New Products
| 编号 | 化学名称 | Cas号 | 纯度 | 化学结构 |
|---|---|---|---|---|
| 20460 | Ro5-3335 | 30195-30-3 | ≧98.0% |  |
| Ro5-3335 是一种亲脂性小分子 RUNX1 抑制剂。 | ||||
| 233901 | RRX-001 | 925206-65-1 | ≧98.0% |  |
| RRx-001 是一种高选择性 NLRP3 抑制剂，具有血管正常化和肿瘤相关的 | ||||
| 230401 | 苯丁酸甘油酯 | 611168-24-2 | ≧98.0% | .png) |
| Glycerol phenylbutyrate 是 sigma-2 (σ2) 受体的一个配体，其 pKi 值 | ||||
| 230403 | (R,S)-BI 1015550 | 1423719-27-0 | ≧98.0% | -BI_1015550_1423719-27-0.png) |
| BI 1015550 is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of P | ||||
| 237072 | AZD0095 | 2750001-23-9 | ≧98.0% |  |
| AZD0095 is a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology. | ||||
| 20508 | AZD5991 | 2143061-81-6 | ≧98.0% |  |
| AZD-5991 是一种有效的选择性 Mcl-1 抑制剂。 | ||||
| 20511 | PDD4091 | 1373651-41-2 | ≧98.0% |  |
| PDD4091 是一种新颖的G6PD抑制剂。 | ||||
| 20512 | BDTX-1535 | 2607829-38-7 | ≧98.0% |  |
| BDTX-1535 是一种突变选择性、不可逆的第四代 EGFR 抑制剂。 | ||||
| 20514 | NMS-293 ( NMS-P293 ) | 1606996-12-6 | ≧98.0% |  |
| NMS-293 是 Nerviano Medical Sciences 处于早期临床开发阶段的 PARP-1 抑制 | ||||
| 20576 | STX-721 | 2765525-82-2 | ≧98.0% |  |
| STX-721 is a next-generation, orally delivered therapy, designed with potential best- | ||||
| 20639 | SOP1812 (QN-302) | 2546091-70-5 | ≧98.0% | _2546091-70-5.png) |
| QN-302 是一种 G4选择性转录抑制剂。 | ||||
| 20640 | AAG-1 ( FLAG-003 ) | 1614235-14-1 | ≧98.0% |  |
| FLAG-003 是一种多效水溶性小分子治疗药物，旨在通过两种成熟的作 | ||||